173 related articles for article (PubMed ID: 31592113)
1. Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine.
Mohammadian M; Zeynali-Moghaddam S; Khadem Ansari MH; Rasmi Y; Fathi Azarbayjani A; Kheradmand F
Adv Pharm Bull; 2019 Aug; 9(3):439-444. PubMed ID: 31592113
[No Abstract] [Full Text] [Related]
2. Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines.
Mohammadian M; Zeynali S; Azarbaijani AF; Khadem Ansari MH; Kheradmand F
Res Pharm Sci; 2017 Dec; 12(6):517-525. PubMed ID: 29204180
[TBL] [Abstract][Full Text] [Related]
3. The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Saito K; Khan K; Yu SZ; Ronson S; Rhee J; Li G; Van Echo D; Suntharalingam M; O'Malley BW; Li D
Laryngoscope; 2009 Jan; 119(1):82-8. PubMed ID: 19117293
[TBL] [Abstract][Full Text] [Related]
4. The Evaluation of Dihydropyrimidine Dehydrogenase Enzyme Level in the Serum of Colorectal Cancer Iraqi Males on Fluoropyrimidine-Based Chemotherapy (Capecitabine).
Challoob MA; Mohammed NS
Cureus; 2023 Sep; 15(9):e44534. PubMed ID: 37790008
[TBL] [Abstract][Full Text] [Related]
5. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
Vallböhmer D; Yang DY; Kuramochi H; Shimizu D; Danenberg KD; Lindebjerg J; Nielsen JN; Jakobsen A; Danenberg PV
Int J Oncol; 2007 Aug; 31(2):413-8. PubMed ID: 17611699
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Wan Y; Hui H; Wang X; Wu J; Sun S
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889.
Endo M; Miwa M; Eda H; Ura M; Tanimura H; Ishikawa T; Miyazaki-Nose T; Hattori K; Shimma N; Yamada-Okabe H; Ishitsuka H
Int J Cancer; 2003 Sep; 106(5):799-805. PubMed ID: 12866042
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
9. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
[TBL] [Abstract][Full Text] [Related]
11. Severe adverse events due to dihydropyrimidine dehydrogenase deficiency in a Japanese patient with colon cancer taking capecitabine: a case report.
Tsutsui M; Yamamoto S; Yoshikawa Y; Nakanishi R; Takano K; Osumi K; Akatsu T; Yoneyama K; Nakagawa M; Kanai T
Int Cancer Conf J; 2018 Oct; 7(4):125-129. PubMed ID: 31149530
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
13. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
Nishimura G; Terada I; Kobayashi T; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Kayahara M; Shimizu K; Ohta T; Miwa K
Oncol Rep; 2002; 9(3):479-82. PubMed ID: 11956613
[TBL] [Abstract][Full Text] [Related]
14. 5-Fluorouracil Chemotherapy for Dihydropyrimidine Dehydrogenase-deficient Patients: Potential of the Dose-escalation Method.
Yoshida Y; Ogura K; Hiratsuka A; Aisu N; Yamada T; Kojima D; Tanimura S; Ogata K; Hara S; Mogi A; Takamatsu Y; Tamura K; Mishima H; Yamashita Y
Anticancer Res; 2015 Sep; 35(9):4881-7. PubMed ID: 26254383
[TBL] [Abstract][Full Text] [Related]
15. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Ichikawa W; Uetake H; Shirota Y; Yamada H; Nishi N; Nihei Z; Sugihara K; Hirayama R
Clin Cancer Res; 2003 Feb; 9(2):786-91. PubMed ID: 12576451
[TBL] [Abstract][Full Text] [Related]
16. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.
Mori K; Hasegawa M; Nishida M; Toma H; Fukuda M; Kubota T; Nagasue N; Yamana H; Hirakawa-YS Chung K; Ikeda T; Takasaki K; Oka M; Kameyama M; Toi M; Fujii H; Kitamura M; Murai M; Sasaki H; Ozono S; Makuuchi H; Shimada Y; Onishi Y; Aoyagi S; Mizutani K; Ogawa M; Nakao A; Kinoshita H; Tono T; Imamoto H; Nakashima Y; Manabe T
Int J Oncol; 2000 Jul; 17(1):33-8. PubMed ID: 10853015
[TBL] [Abstract][Full Text] [Related]
17. Anti-cancer effects of chemotherapeutic agent; 17-AAG, in combined with gold nanoparticles and irradiation in human colorectal cancer cells.
Moradi Z; Mohammadian M; Saberi H; Ebrahimifar M; Mohammadi Z; Ebrahimpour M; Behrouzkia Z
Daru; 2019 Jun; 27(1):111-119. PubMed ID: 30835081
[TBL] [Abstract][Full Text] [Related]
18. Toxicity Associated with Capecitabine in Patients Suffering from Dihydropyrimidine Dehydrogenase Deficiency.
Bermejo-Pérez MJ; Galeote-Miguel AM; Rodelo-Haad LE; Alés-Díaz I; Durán-Ogalla G; Benavides-Orgaz M
Chemotherapy; 2014; 60(5-6):353-5. PubMed ID: 26330092
[TBL] [Abstract][Full Text] [Related]
19. Choice of Capecitabine or S1 in Combination with Oxaliplatin based on Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase Expression Status in Patients with Advanced Gastric Cancer.
Xu R; He X; Wufuli R; Su Y; Ma L; Chen R; Han Z; Wang F; Liu J
J Gastric Cancer; 2019 Dec; 19(4):408-416. PubMed ID: 31897343
[TBL] [Abstract][Full Text] [Related]
20. The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.
Hasegawa K; Okamoto H; Kawamura K; Kato R; Kobayashi Y; Sekiya T; Udagawa Y
Eur J Obstet Gynecol Reprod Biol; 2012 Jul; 163(1):67-70. PubMed ID: 22480411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
